CLINICAL_TRIALS ClinicalTrials.gov record update

Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00620516
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:35.984133+00:00
Published At: 2013-11-19T00:00:00+00:00
Record Updated At: 2013-11-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pulmonary Disease, Chronic Obstructive"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2013-11-19"
protocolSection.identificationModule.nctId: "NCT00620516"
protocolSection.identificationModule.officialTitle: "Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva\u00ae HandiHaler\u00ae (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.